GlassScriptPhysician profile
Gerald M Isbell
NPI 1093774853
$1,545.52
in general payments reported to CMS, 2019-2025
20 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $230 · 2021: $33.83 · 2022: $39.53 · 2023: $237 · 2024: $60.24 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.41 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.52 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Allergan, INC. | $178.09 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $138.43 | 2022-2025 | Dupixent |
| Pfizer INC. | $127.72 | 2019 | |
| Ardelyx, INC. | $78.68 | 2025 | Ibsrela |
| Shionogi INC | $76.89 | 2019 | |
| Romark Laboratories, Lc | $67.53 | 2019-2020 | |
| Braintree Laboratories, INC. | $53.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.44 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $40.51 | 2019-2023 | Clenpiq |
| Ironwood Pharmaceuticals, INC | $32.76 | 2019 | |
| Janssen Biotech, INC. | $32.68 | 2019-2025 | Tremfya |
| Madrigal Pharmaceuticals | $27.83 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $25.10 | 2025 | Apollo Esg System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $19.95 | 2025 | Heplisav-B |
| Daiichi Sankyo INC. | $18.98 | 2020 | |
| Qol Medical, LLC | $18.32 | 2020 | |
| Celltrion USA INC. | $16.82 | 2024 | Vegzelma |
| Endo Pharmaceuticals INC. | $15.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Isbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.